London, United Kingdom
04 Jul 2018
Reference No: M1802263-MAFApply for this event
Topics to be covered will include:-
4 July 2018
GBP price excludes VAT @20%
The new Pharmacovigilance Legislation of 2012 now requires companies to provide Risk Management Plans (RMPs) and assessments for all new products whether those products are generic products or new chemical entities. If these are not done correctly this can delay both licensure and sales and damage the Company ability to maximise its products. Maintenance of the RMPs also is an important aspect for maintaining the licence, compliance and these are reviewed in Regulatory Inspections. Can you afford not to get this right?